Somatostatin receptor subtypes: Targeting functional and therapeutic specificity

Annales d'Endocrinologie

Volumn 63, Issue 2 III, 2002, Pages

  Culler, M D ^a   Taylor, J E ^a   Moreau, J P ^a  

^a Biomeasure Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIM 23197; BIM 23244; BIM 23268; BIM 23627; BIM 23787; BIM 23867; BIM 23926; BIM 23A108; BN 81668; CAS 3 15 5; DOPAMINE; GROWTH HORMONE; L 363377; L 786778; L 796779; L 797591; L 803087; OCTREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; GROWTH HORMONE RELEASE; HORMONE RECEPTOR INTERACTION; HUMAN; MOLECULAR RECOGNITION; NONHUMAN; STRUCTURE ACTIVITY RELATION; THYROID MEDULLARY CARCINOMA;

ANIMALS; DOPAMINE; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; THYROID NEOPLASMS;

EID: 0036102270     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
2. Species differences between male rat and ram pituitary somatostatin receptors involved in the inhibition of growth hormone secretion
3. Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat
4. Chimeric analogs of somatostatin in pituitary adenoma
5. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly
6. Domain swapping in G-protein coupled receptor dimers
7. Structural and functional aspects of G protein-coupled receptor oligomerization
8. Somatostatin analogs: Clinical application in relation to human somatostatin receptor subtypes
9. Human somatostatin receptor subtypes in acromegaly: Distict patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes
10. G-protein-coupled receptor heterodimerization modulates receptor function
11. Immuno-histochemical localization of somatostatin receptor type 2A in rat and human tissues
12. Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide
13. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients
14. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients
15. Molecular biology of somatostatin receptor subtypes
16. Cloned somatostatin receptors: Identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides
17. Somatostatin (Part 1)
18. Somatostatin (Part 2)
19. Molecular biology of somatostatin receptors
20. Distribution of somatostatin receptors in normal and neoplastic human tissues: Recent advances and potential relevance
21. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers
22. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
23. BIM-23244, a somatostatin receptor subtype 2- and 5- selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas
24. Somatostatin receptors present knowledge and future directions
25. Half-life of somatostatin-like immunoreactivity in canine plasma
26. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man
27. Management of pituitary tumors
28. Somatostatin receptor sub-type specificity in human fetal pituitary cultures: Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation
29. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas: Novel potential therapy for functional pituitary tumors
30. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT